Jonathan Smith, Author at Labiotech.eu

About

Reporter for Labiotech. I hail from the UK. I was born in Bristol, studied Neuroscience in the University of Bristol, and trained mice in Eisai, Hertfordshire, for one year. I then tickled locusts for my Ph.D. at the University of Leicester, before eventually ending up here!
Out of the office, I travel, play video games and board games, drink beer and play the piano.

Articles by Jonathan Smith

News and Trends 13 Dec 2019

Transgene’s Cancer Vaccine Abandoned after Phase II Fail

French biotech Transgene has ceased the development of a therapeutic cancer vaccine that failed to shrink tumors in patients with lung cancer in a phase II trial. In the phase II trial, Transgene tested its therapeutic cancer vaccine in combination with chemotherapy and the checkpoint inhibitor drug nivolumab, marketed as Opdivo. The treatment failed to […]

December 13, 2019 - 2 minutesmins - By Jonathan Smith

antibiotic resistance iterum therapeutics

News and Trends 12 Dec 2019

Iterum Therapeutics Reels from Antibiotic Phase III Fail

An antibiotic candidate developed by the Irish company Iterum Therapeutics has failed to meet the main goal of a phase III trial, a blow for efforts to meet the challenge of global antibiotic resistance. Iterum Therapeutics’ drug sulopenem was tested in a phase III trial that recruited 674 patients suffering from complicated intra-abdominal infections. These […]

December 12, 2019 - 2 minutesmins - By Jonathan Smith

cancer immunotherapy immunos therapeutics

News and Trends 11 Dec 2019

€14M Series A to Fund Cancer Immunotherapy Boosting Checkpoint Inhibitors

The Swiss biotech ImmunOs Therapeutics has raised a Series A round of €13.7M (CHF 15M) that will fund the first human trials of its cancer immunotherapy that could improve the response of cancer patients to checkpoint inhibitors. The round was co-led by the Swiss life sciences venture capital firm BioMedPartners and by Pfizer Ventures. The […]

December 11, 2019 - 2 minutesmins - By Jonathan Smith

Interview 11 Dec 2019

Collaboration Between Founders and Investors Primes Biotech Startups for Success

How can entrepreneurs work with investors to maximize the chances of their company succeeding? Venture capital partner Nanna Lüneborg and biotech entrepreneur Mai-Britt Zocca spoke at Labiotech Refresh in Copenhagen about their experiences in founding IO Biotech, a Danish biotech startup that develops cancer immunotherapies. Zocca and Lüneborg were both involved in setting up IO […]

December 11, 2019 - 5 minutesmins - By Jonathan Smith

More News! 10 Dec 2019

ObsEva’s Oral Treatment for Uterine Fibroids Nails Phase III

An oral drug developed by the Swiss company ObsEva was shown to reduce menstrual bleeding and pain caused by uterine fibroids. The phase III trial tested ObsEva’s drug candidate linzagolix in 535 women suffering from heavy menstrual bleeding caused by benign tumors in the uterus called uterine fibroids. The effects of the drug were compared […]

December 10, 2019 - 2 minutesmins - By Jonathan Smith

dna data storage self replicating machine

News and Trends 9 Dec 2019

Scientists Use DNA Data Storage to Hide Information in Everyday Objects

Scientists have developed a method for storing DNA data in 3D-printed objects, which could one day allow machines to replicate themselves. The group, based at ETH Zurich, Switzerland, as well as in Israel and the US, began by synthesizing DNA molecules that encode blueprints of the Stanford bunny, a rabbit-shaped object commonly used in testing […]

December 9, 2019 - 4 minutesmins - By Jonathan Smith

colorectal cancer mologen cancer immunotherapy

News and Trends 6 Dec 2019

Update: Cancer Immunotherapy Biotech Files for Insolvency

Update (06/12/2019): Following the phase III failure of its immunotherapy drug for colorectal cancer in the summer, the German company Mologen has filed for insolvency. Published 06/08/2019 A DNA immunotherapy drug developed by the German company Mologen has failed to improve the survival of patients with colorectal cancer in a phase III trial. The phase […]

December 6, 2019 - 2 minutesmins - By Jonathan Smith

acute heart failure 4teen4 pharmaceuticals

More News! 5 Dec 2019

German Biotech Raises €7M Series A to Treat Acute Heart Failure

4TEEN4 Pharmaceuticals has raised a Series A round of €6.9M to fuel the development of a first-in-class antibody drug that could reduce mortality in acute heart failure. The round was led by Brandenburg Kapital, a subsidiary of the German investment bank Investitionsbank des Landes Brandenburg. Other investors in the round, including business angels and private […]

December 5, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 4 Dec 2019

€48M Series B Fuels Immunotherapies for Cancer and Autoimmune Diseases

ImCheck Therapeutics has raised a Series B round worth €48M to fund the development of first-in-class immunotherapies that treat cancer and autoimmune diseases by targeting a rare type of immune cells called a gamma delta T-cell. ImCheck Therapeutics’ Series B round was led by Pfizer Ventures — the venture capital arm of the big pharma […]

December 4, 2019 - 3 minutesmins - By Jonathan Smith

More News! 3 Dec 2019

Sensorion’s Vertigo Drug Abandoned in Phase II

A small molecule drug developed by the French company Sensorion has proven ineffective in a phase IIb trial for the treatment of a rare vertigo condition, leading the company to close down the development of the drug. The phase IIb trial tested Sensorion’s lead drug in 105 patients with the rare condition acute unilateral vestibulopathy, […]

December 3, 2019 - 2 minutesmins - By Jonathan Smith

diabeloop artificial pancreas type 1 diabetes

News and Trends 2 Dec 2019

€31M Series B Funds Rollout of Artificial Pancreas in Type 1 Diabetes

The French biotech Diabeloop has raised €31M to launch an artificial pancreas device designed to automatically control the blood glucose levels of type 1 diabetes patients. According to Diabeloop, this is the biggest Series B round raised by a European company developing therapies that use artificial intelligence. The round was led by the French family […]

December 2, 2019 - 3 minutesmins - By Jonathan Smith

contraception medincell bill and melinda gates foundation

More News! 29 Nov 2019

MedinCell Granted €17M to Develop Cheap Long-Acting Contraception

The French company MedinCell has received a €17.3M ($19M) grant from the Bill and Melinda Gates Foundation to advance its long-acting contraceptive implant to human trials. The grant is a follow-on to a €3.2M endowment from the Gates Foundation in 2017 to fuel early preclinical development of the implant. The additional funds will help MedinCell […]

November 29, 2019 - 2 minutesmins - By Jonathan Smith

Knowledge hub

Categories

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Approaches

Therapeutic areas

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Jonathan Smith

About

Articles by Jonathan Smith

Transgene’s Cancer Vaccine Abandoned after Phase II Fail

Iterum Therapeutics Reels from Antibiotic Phase III Fail

€14M Series A to Fund Cancer Immunotherapy Boosting Checkpoint Inhibitors

Collaboration Between Founders and Investors Primes Biotech Startups for Success

ObsEva’s Oral Treatment for Uterine Fibroids Nails Phase III

Scientists Use DNA Data Storage to Hide Information in Everyday Objects

Update: Cancer Immunotherapy Biotech Files for Insolvency

German Biotech Raises €7M Series A to Treat Acute Heart Failure

€48M Series B Fuels Immunotherapies for Cancer and Autoimmune Diseases

Sensorion’s Vertigo Drug Abandoned in Phase II

€31M Series B Funds Rollout of Artificial Pancreas in Type 1 Diabetes

MedinCell Granted €17M to Develop Cheap Long-Acting Contraception

Subscribe to our newsletter to get the latest biotech news!

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Jonathan Smith

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!